OncoSec Medical Incorporated Presents at 2013 BIO International Convention, Apr-24-2013 09:00 AM. Venue: McCormick Place - Chicago Bulls Room, 2301 S. Lake Shore Drive, Chicago, IL 60616, United States.

OncoSec Medical Inc. announced positive, durable response results in an update on interim data from its Phase II metastatic melanoma trial. In this analysis, all melanoma lesions that demonstrated at least a partial or complete response (PR or CR) to treatment with ImmunoPulse were followed, to determine durable response. 68% and 45% of treated lesions demonstrated a durable response at three and six months, respectively. These interim results reinforce previously announced Phase I data demonstrating that ImmunoPulse therapy is safe and well tolerated, as well as producing robust objective response rates, in patients with metastatic melanoma. OncoSec expects to complete enrollment of approximately 25 patients in total, in second quarter of 2013, with final analysis anticipated in fourth quarter of 2013.

OncoSec Medical Incorporated, Annual General Meeting, Apr 15, 2013., at 09:00 US Eastern Standard Time. Location: principal executive offices at 4690 Executive Drive, Suite 250. Agenda: To elect four directors to Board of Directors to serve for a term of one year or until their successors are duly elected and qualified; to ratify the appointment of Mayer Hoffman McCann P.C. as the company's independent registered public accounting firm for the fiscal year ending July 31, 2013; to approve an amendment to the company's 2011 stock incentive Plan to authorize the issuance of an additional 3,800,000 shares of common stock under the Plan; to approve, on an advisory basis, the compensation of named executive officers; to vote, on an advisory basis, on the frequency of holding an advisory vote on the compensation of named executive officers; and to transact other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.